{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:29:06Z","timestamp":1776407346389,"version":"3.51.2"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T00:00:00Z","timestamp":1416528000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/2050-6511-15-64","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T04:01:42Z","timestamp":1416542502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine"],"prefix":"10.1186","volume":"15","author":[{"given":"Zhi-duo","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng-yu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing Yu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,21]]},"reference":[{"issue":"8","key":"348_CR1","first-page":"1816","volume":"30","author":"QY Zeng","year":"2003","unstructured":"Zeng QY: Ankylosing spondylitis in Shantou, China: 15\u00a0years' clinical experience. J Rheumatol. 2003, 30 (8): 1816-1821.","journal-title":"J Rheumatol"},{"issue":"8","key":"348_CR2","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/ard.51.8.955","volume":"51","author":"M Dougados","year":"1992","unstructured":"Dougados M, Maetzel A, Mijiyawa M, Amor B: Evaluation of sulphasalazine in the treatment of spondyloarthropathies. Ann Rheum Dis. 1992, 51 (8): 955-958. 10.1136\/ard.51.8.955.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"348_CR3","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","volume":"42","author":"DO Clegg","year":"1999","unstructured":"Clegg DO, Reda DJ, Abdellatif M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999, 42 (11): 2325-2329. 10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"348_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s003930200024","volume":"61","author":"WA Schmidt","year":"2002","unstructured":"Schmidt WA, Wierth S, Milleck D, Droste U, Gromnica-Ihle E: Sulfasalazine in ankylosing spondylitis: a prospective, randomized, double-blind placebo-controlled study and comparison with other controlled studies. Z Rheumatol. 2002, 61 (2): 159-167. 10.1007\/s003930200024.","journal-title":"Z Rheumatol"},{"issue":"8","key":"348_CR5","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.1780390819","volume":"39","author":"AGP Taggart","year":"1996","unstructured":"Taggart AGP, McEvoy FHR, Bird H: Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study. Arthritis Rheum. 1996, 39 (8): 1400-1405. 10.1002\/art.1780390819.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"348_CR6","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1248\/bpb.25.1058","volume":"25","author":"Y Tanigawara","year":"2002","unstructured":"Tanigawara Y, Kita T, Aoyama N, Gobara M, Komada F, Sakai T, Kasuga M, Hatanaka H, Sakaeda T, Okumura K: N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events. Biol Pharm Bull. 2002, 25 (8): 1058-1062. 10.1248\/bpb.25.1058.","journal-title":"Biol Pharm Bull"},{"issue":"Suppl 2","key":"348_CR7","doi-asserted-by":"publisher","first-page":"S212","DOI":"10.1002\/ibd.20712","volume":"14","author":"B Moum","year":"2008","unstructured":"Moum B: Which are the 5-ASA compound side effects and how is it possible to avoid them. Inflamm Bowel Dis. 2008, 14 (Suppl 2): S212-S213.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"348_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2165\/00003088-198510040-00001","volume":"10","author":"U Klotz","year":"1985","unstructured":"Klotz U: Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugsof 5-aminosalicylic acid. Clin Pharmacokinet. 1985, 10 (4): 285-302. 10.2165\/00003088-198510040-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"13","key":"348_CR9","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.2165\/00003495-200565130-00008","volume":"65","author":"GL Plosker","year":"2005","unstructured":"Plosker GL, Croom KF: Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs. 2005, 65 (13): 1825-1849. 10.2165\/00003495-200565130-00008.","journal-title":"Drugs"},{"issue":"1","key":"348_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5414\/CPP48001","volume":"48","author":"UD Kuhn","year":"2010","unstructured":"Kuhn UD, Anschutz M, Schmucker K, Schug BS, Hippius M, Blume HH: Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics. Int J Clin Pharmacol Ther. 2010, 48 (1): 1-10. 10.5414\/CPP48001.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"348_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00008571-199502000-00001","volume":"5","author":"KP Vatsis","year":"1995","unstructured":"Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y: Nomenclature for N-acetyltransferases. Pharmacogenetics. 1995, 5 (1): 1-17. 10.1097\/00008571-199502000-00001.","journal-title":"Pharmacogenetics"},{"issue":"5\u20136","key":"348_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/10937400903158383","volume":"12","author":"K Walker","year":"2009","unstructured":"Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B: Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health B Crit Rev. 2009, 12 (5\u20136): 440-472.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"348_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1146\/annurev.pharmtox.37.1.269","volume":"37","author":"UA Meyer","year":"1997","unstructured":"Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997, 37: 269-296. 10.1146\/annurev.pharmtox.37.1.269.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"348_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1517\/17425250902877698","volume":"5","author":"DW Hein","year":"2009","unstructured":"Hein DW: N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understandingcomplexities of personalized medicine. Expert Opin Drug Metab Toxicol. 2009, 5 (4): 353-366. 10.1517\/17425250902877698.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"348_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1067\/mcp.2002.126740","volume":"72","author":"A Pawlik","year":"2002","unstructured":"Pawlik A, Ostanek L, Brzosko I, Gawroska-Szklarz B, Brzosko M, Dabrowska-Zamojcin E: Increased genotype frequency of N-acetyltransferase 2 slow acetylation inpatients with rheumatoid arthritis. Clin Pharmacol Ther. 2002, 72 (3): 319-325. 10.1067\/mcp.2002.126740.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"348_CR16","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1007\/s10620-010-1527-4","volume":"56","author":"M Baranska","year":"2011","unstructured":"Baranska M, Trzcinski R, Dziki A, Rychlik-Sych M, Dudarewicz M, Skretkowicz J: The role of N-acetyltransferase 2 polymorphism in the etiopathogenesis of inflammatory bowel disease. Dig Dis Sci. 2011, 56 (7): 2073-2080. 10.1007\/s10620-010-1527-4.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"348_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/art.33408","volume":"64","author":"TR Mikuls","year":"2012","unstructured":"Mikuls TR, Levan T, Gould KA, Yu F, Thiele GM, Bynote KK, Conn D, Jonas BL, Callahan LF, Smith E, Brasington R, Moreland LW, Reynolds R, Gaffo A, Bridges SL: Interactions of cigarette smoking with NAT2 polymorphisms on rheumatoid arthritis risk in African Americans. Arthritis Rheum. 2012, 64 (3): 655-664. 10.1002\/art.33408.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"348_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1365-2230.2004.01685.x","volume":"30","author":"L Tamer","year":"2005","unstructured":"Tamer L, Tursen U, Eskandari G, Ates NA, Ercan B, Yildirim H, Atik U: N-acetyltransferase 2 polymorphisms in patients with Behcet's disease. Clin Exp Dermatol. 2005, 30 (1): 56-60. 10.1111\/j.1365-2230.2004.01685.x.","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"348_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1177\/0961203309102809","volume":"18","author":"C Kiyohara","year":"2009","unstructured":"Kiyohara C, Washio M, Horiuchi T, Tada Y, Asami T, Ide S, Takahashi H, Kobashi G, Kyushu Sapporo SLE (KYSS) Study Group: Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupuserythematosus in a Japanese population. Lupus. 2009, 18 (7): 630-638. 10.1177\/0961203309102809.","journal-title":"Lupus"},{"issue":"10","key":"348_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/rheumatology\/36.10.1089","volume":"36","author":"I Gunnarsson","year":"1997","unstructured":"Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B: Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol. 1997, 36 (10): 1089-1094. 10.1093\/rheumatology\/36.10.1089.","journal-title":"Br J Rheumatol"},{"issue":"9486","key":"348_CR21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0140-6736(05)67137-1","volume":"366","author":"M Garc\u00eda-Closas","year":"2005","unstructured":"Garc\u00eda-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tard\u00f3n A, Serra C, Carrato A, Garc\u00eda-Closas R, Lloreta J, Casta\u00f1o-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Tor\u00e0 M, Fern\u00e1ndez F, Real FX, Rothman N: NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005, 366 (9486): 649-659. 10.1016\/S0140-6736(05)67137-1.","journal-title":"Lancet"},{"issue":"3","key":"348_CR22","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s10549-010-0807-1","volume":"123","author":"J Zhang","year":"2010","unstructured":"Zhang J, Qiu LX, Wang ZH, Wang JL, He SS, Hu XC: NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2010, 123 (3): 877-883. 10.1007\/s10549-010-0807-1.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"348_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1124\/pr.110.004275","volume":"64","author":"NJ Butcher","year":"2012","unstructured":"Butcher NJ, Minchin RF: Arylamine N-acetyltransferase 1: a novel drug target in cancer development. Pharmacol Rev. 2012, 64 (1): 147-165. 10.1124\/pr.110.004275.","journal-title":"Pharmacol Rev"},{"issue":"16","key":"348_CR24","first-page":"3537","volume":"55","author":"DA Bell","year":"1995","unstructured":"Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H, Strange RC: Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res. 1995, 55 (16): 3537-3542.","journal-title":"Cancer Res"},{"issue":"10","key":"348_CR25","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1248\/bpb.24.1176","volume":"24","author":"T Kita","year":"2001","unstructured":"Kita T, Sakaeda T, Adachi S, Sakai T, Aoyama N, Hatanaka H, Kasuga M, Okumura K: N-Acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects. Biol Pharm Bull. 2001, 24 (10): 1176-1180. 10.1248\/bpb.24.1176.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"348_CR26","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1023\/B:PHAM.0000016246.84974.ec","volume":"21","author":"S Kumagai","year":"2004","unstructured":"Kumagai S, Komada F, Kita T, Morinobu A, Ozaki S, Ishida H, Sano H, Matsubara T, Okumura K: N-Acetyltransferase 2 Genotype-Related Efficacy of Sulfasalazine in patients with Rheumatoid Arthritis. Pharm Res. 2004, 21 (2): 324-329.","journal-title":"Pharm Res"},{"issue":"5","key":"348_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00228-006-0110-6","volume":"62","author":"B Chen","year":"2006","unstructured":"Chen B, Zhang WX, Cai WM: The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. Eur J Clin Pharmacol. 2006, 62 (5): 355-359. 10.1007\/s00228-006-0110-6.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1\u20132","key":"348_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cca.2009.06.025","volume":"407","author":"JJ Ma","year":"2009","unstructured":"Ma JJ, Liu CG, Li JH, Cao XM, Sun SL, Yao X: Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clin Chim Acta. 2009, 407 (1\u20132): 30-35.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"348_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/gm409","volume":"5","author":"AK Daly","year":"2013","unstructured":"Daly AK: Pharmacogenomics of adverse drug reactions. Genome Med. 2013, 5 (1): 5-10.1186\/gm409.","journal-title":"Genome Med"},{"issue":"4","key":"348_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984, 27 (4): 361-368. 10.1002\/art.1780270401.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"348_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1155\/2007\/976804","volume":"21","author":"M Chen","year":"2007","unstructured":"Chen M, Xia B, Chen B, Guo Q, Li J, Ye M, Hu Z: N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. Can J Gastroenterol. 2007, 21 (3): 155-158.","journal-title":"Can J Gastroenterol"},{"issue":"2","key":"348_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.berh.2004.02.006","volume":"18","author":"E Tanaka","year":"2004","unstructured":"Tanaka E, Taniguchi A, Urano W, Yamanaka H, Kamatani N: Pharmacogenetics of disease-modifying anti-rheumatic drugs. Best Pract Res Clin Rheumatol. 2004, 18 (2): 233-247. 10.1016\/j.berh.2004.02.006.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9237","key":"348_CR33","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK: Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000, 356 (9237): 1255-1259. 10.1016\/S0140-6736(00)02799-9.","journal-title":"Lancet"},{"issue":"13","key":"348_CR34","first-page":"5051","volume":"61","author":"I Cascorbi","year":"2001","unstructured":"Cascorbi I, Roots I, Brockmoller J: Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res. 2001, 61 (13): 5051-5056.","journal-title":"Cancer Res"},{"issue":"6","key":"348_CR35","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/art.30223","volume":"63","author":"J Braun","year":"2011","unstructured":"Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, Freundlich B: Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011, 63 (6): 1543-1551. 10.1002\/art.30223.","journal-title":"Arthritis Rheum"},{"issue":"6544","key":"348_CR36","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/bmj.293.6544.420","volume":"293","author":"RS Amos","year":"1986","unstructured":"Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B: Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11\u00a0years. Br Med J (Clin Res Ed). 1986, 293 (6544): 420-423. 10.1136\/bmj.293.6544.420.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"12","key":"348_CR37","first-page":"2492","volume":"29","author":"E Tanaka","year":"2002","unstructured":"Tanaka E, Taniguchi A, Urano W, Nakajima H, Matsuda Y, Kitamura Y, Saito M, Yamanaka H, Saito T, Kamatani N: Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol. 2002, 29 (12): 2492-2499.","journal-title":"J Rheumatol"},{"issue":"4","key":"348_CR38","first-page":"724","volume":"35","author":"M Soejima","year":"2008","unstructured":"Soejima M, Kawaguchi Y, Hara M, Kamatani N: Prospective study of the association between NAT2 gene haplotypes and severeadverse events with sulfasalazine therapy in patients with rheumatoid arthritis. J Rheumatol. 2008, 35 (4): 724-","journal-title":"J Rheumatol"},{"issue":"2","key":"348_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00008571-199704000-00006","volume":"7","author":"N Sabbagh","year":"1997","unstructured":"Sabbagh N, Delaporte E, Marez D, Lo-Guidice JM, Piette F, Broly F: NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoidlupus erythematosus. Pharmacogenetics. 1997, 7 (2): 131-135. 10.1097\/00008571-199704000-00006.","journal-title":"Pharmacogenetics"},{"issue":"7","key":"348_CR40","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1111\/j.1572-0241.2002.05838.x","volume":"97","author":"E Ricart","year":"2002","unstructured":"Ricart E, Taylor WR, Loftus EV, O'Kane D, Weinshilboum RM, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ: N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol. 2002, 97 (7): 1763-1768. 10.1111\/j.1572-0241.2002.05838.x.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"348_CR41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3109\/03009749209099228","volume":"21","author":"GD Kitas","year":"1992","unstructured":"Kitas GD, Farr M, Waterhouse L, Bacon PA: Influence of acetylator status on sulphasalazine efficacy and toxicity inpatients with rheumatoid arthritis. Scand J Rheumatol. 1992, 21 (5): 220-225. 10.3109\/03009749209099228.","journal-title":"Scand J Rheumatol"},{"issue":"10","key":"348_CR42","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/FPC.0b013e3283498ee9","volume":"21","author":"D Wang","year":"2011","unstructured":"Wang D, Para MF, Koletar SL, Sadee W: Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Pharmacogenet Genomics. 2011, 21 (10): 652-664. 10.1097\/FPC.0b013e3283498ee9.","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"348_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/00008571-199712000-00009","volume":"7","author":"HG Xie","year":"1997","unstructured":"Xie HG, Xu ZH, Ou-Yang DS, Shu Y, Yang DL, Wang JS, Yan XD, Huang SL, Wang W, Zhou HH: Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. Pharmacogenetics. 1997, 7 (6): 503-514. 10.1097\/00008571-199712000-00009.","journal-title":"Pharmacogenetics"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-15-64.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2050-6511-15-64\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-15-64","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-15-64.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T06:40:01Z","timestamp":1630564801000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/2050-6511-15-64"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,21]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["348"],"URL":"https:\/\/doi.org\/10.1186\/2050-6511-15-64","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,21]]},"assertion":[{"value":"12 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"64"}}